Daily AI-curated articles on clinical trials, FDA updates, and pharmaceutical insights.
Novo Nordisk gains market advantage as Lilly's oral Foundayo faces slower-than-expected launch trajectory in the competitive oral GLP-1 weight-loss drug sector.
Executive Order directs HHS to fast-track treatments for serious mental illness, creating new pathways for clinical research in treatment-resistant conditions.
FDA issues recall for Codman Disposable Perforators due to device disassembly risks during neurosurgery, highlighting critical device safety concerns for clinical sites.
Atlanta-area clinical trial evaluates treat-to-target approach for gout prevention, focusing on uric acid reduction to achieve flare-free outcomes in recurring patients.
The Biotechnology Innovation Organization's new nationwide campaign highlights biotech breakthroughs and their patient impact, signaling industry priorities for CROs and researchers.
FDA encourages testosterone therapy sponsors to pursue new indication for low libido in men with idiopathic hypogonadism, signaling potential regulatory pathway expansion.
American Contract Systems' Namic RA syringes face safety concerns as adaptors may unwind during use, risking infection, blood loss, and air embolism in clinical procedures.
The FORWARD clinical trial is evaluating esreboxetine (AXS-14) as a potential fibromyalgia treatment, offering new hope for patients with chronic pain conditions.
